Editas Medicine, Inc. is a pioneering clinical-stage genome editing company dedicated to developing groundbreaking genomic therapies for a variety of serious diseases. The company utilizes a proprietary gene editing platform based on CRISPR technology and is advancing several notable projects. Among these is EDIT-101, which is currently in a Phase 1/2 clinical trial for Leber Congenital Amaurosis 10, a genetic disorder that results in childhood blindness. Additionally, Editas is working on EDIT-102 to treat Usher Syndrome 2A, a condition characterized by retinitis pigmentosa accompanied by hearing loss, as well as autosomal dominant retinitis pigmentosa, a progressive retinal degeneration. Furthermore, the company is developing EDIT-301 for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia. Editas is also exploring innovative gene-edited Natural Killer cell therapies for solid tumor cancers, alpha-beta T cells for various cancers, and gamma delta T cell therapies focused on cancer treatment. In parallel, the company has initiated an early discovery program aimed at developing a therapy for a neurological disease. Collaboratively, Editas has established partnerships with Juno Therapeutics, Inc., Allergan Pharmaceuticals International Limited, and Asklepios BioPharmaceutical, Inc. to leverage shared expertise in engineered T cells and gene editing for diverse applications, including ocular disorders and neurological diseases. The company reported depreciation and amortization expenses of $5,809,000.00 reflecting the wear and tear of its assets. The weighted average number of shares outstanding is 82,338,220.00 highlighting the company's shareholder base. The earnings per share (EPS) is reported at -$2.88 indicating the company's profitability on a per-share basis, while the cost of revenue for the company is $0.00 showcasing its production and operational expenses. Furthermore, the company earned an interest income of $14,062,000.00 showcasing its financial investments. Despite its ambitious goals in medical innovation, Editas Medicine remains accessible to a wide range of investors. The stock is affordable at $2.83 making it suitable for budget-conscious investors. It also has a high average trading volume of 2,508,395.00 indicating strong liquidity, which is advantageous for those looking to enter or exit positions. With a market capitalization of $215,744,780.00 the company is classified as a small-cap player within the biotechnology landscape. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and belongs to the Healthcare sector, driving innovation and growth. The future outlook appears promising, as the company continues to work towards advancing its groundbreaking therapies and innovative solutions for debilitating diseases.